News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Siren Biotechnology and Catalent Announce Collaboration for Manufacturing AAV Gene Therapies Aimed at Cancer
Thursday, May 09, 2024Siren Biotechnology the pioneers behind Universal AAV ImmunoGene Therapy for Cancer have teamed up with Catalent Inc a renowned provider of advanced treatments worldwide in a strategic collaboration
Aspaveli® (pegcetacoplan) Gets Green Light in Europe for Treatment-Naïve Adult Patients with PNH
Thursday, May 09, 2024Sobi has announced that the European Commission has granted approval for an expanded indication for Aspaveli in treating adult patients with paroxysmal nocturnal haemoglobinuria who suffer
Theragent and Pluristyx Announce Collaboration to Accelerate Development of iPSC-based Therapies
Wednesday, May 08, 2024Theragent Inc a prominent Contract Development and Manufacturing Organization specializing in advancing cuttingedge cell and tissuebased therapies has announced a significant collaboration
IRLAB Embarks on Development Collaboration for IRL757, a Promising Treatment for Apathy
Wednesday, May 08, 2024IRLAB Therapeutics AB has entered into a collaboration with the McQuade Center for Strategic Research and Development LLC a part of the Otsuka pharmaceutical family
ARTBIO and Nucleus RadioPharma Team Up to Produce GMP-Grade Therapeutic Products Featuring Radioisotope Pb-212 in Support of Emerging Clinical Trials
Wednesday, May 08, 2024ARTBIO Inc a company focused on clinicalstage radiopharmaceutical development specializing
Eisbach Bio Receives FDA Clearance for IND Application of EIS-12656, a First-in-Class Allosteric Inhibitor Targeting ALC1
Tuesday, May 07, 2024Eisbach Bio GmbH a privatelyheld biotech company pioneering cancer treatment innovations has reached a significant milestone the United States Food and Drug Administration has cleared
Chiesi and Gossamer Bio Collaborate Globally to Develop and Commercialize Seralutinib for Pulmonary Arterial Hypertension and Other Respiratory Disorders
Tuesday, May 07, 2024Chiesi Farmaceutici SpA also known as Chiesi Group and Gossamer Bio Inc a biopharmaceutical company focused on seralutinib for treating pulmonary hypertension have entered into a global
IRLAB Granted Approval by Swedish Medical Products Agency for Phase I Trial of IRL757 Drug Candidate
Monday, May 06, 2024IRLAB Therapeutics AB has recently received approval from the Swedish Medical Products Agency to commence a Phase I clinical trial for their potential treatment for Parkinsons disease
AMO Pharma Wraps Up FDA Consultation, Reveals Strategy for Advancing AMO-02 (tideglusib) in Myotonic Dystrophy Therapy
Friday, May 03, 2024AMO Pharma Limited a company specializing in rare genetic disorders has shared updates on its plans for advancing the development of AMO to treat Type myotonic dystrophy
Delphia Therapeutics Introduces a Novel Field in Cancer Medicine: Activation Lethality
Friday, May 03, 2024Delphia Therapeutics Inc unveiled its groundbreaking mission today to pioneer a fresh frontier in cancer biology called activation lethality aiming to exploit cancers unexpected susceptibility to oncogene
